The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | How may the potential approval of rusfertide impact the treatment landscape for PV?
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses how the potential FDA approval of rusfertide could impact the treatment landscape for polycythemia vera (PV), highlighting that a reduction in frequent phlebotomies will significantly reduce strain on patients. Dr Kuykendall outlines how rusfertide may fit in the treatment algorithm and benefit various patients differently. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
